Clinical Trials Logo

Neoplasm Metastasis clinical trials

View clinical trials related to Neoplasm Metastasis.

Filter by:

NCT ID: NCT06202404 Recruiting - Metastasis Clinical Trials

Predicting Tumor Metastasis by Employing a Target Organ/Primary Lesion Fusion Radiomics Model

Start date: January 1, 2024
Phase:
Study type: Observational

A pre-metastatic target organ/primary lesion fusion radiomics model was developed based on the "soil-seed" theory to predict comman tumor metastasis in retrospective settings. To prospectively verify the performance of the target organ/primary lesion fusion radiomics model in predicting tumor metastasis patterns (brain metastasis in lung cancer, liver metastasis in colorectal cancer, lung metastasis in breast cancer), we designed this prospective observational trial.

NCT ID: NCT06200831 Recruiting - Colorectal Cancer Clinical Trials

Simultaneous vs. Staged Resection of Colorectal Cancer With Synchronous Liver Metastases

SYLMET
Start date: June 1, 2024
Phase: N/A
Study type: Interventional

The SYLMET Trial is a randomized trial to compare simultaneous and two-staged resection of primary colorectal and synchronous liver metastases. This is an investigator-initiated, multicentre, randomized controlled trial to assess complications (primary endpoint), survival, cost-effectiveness, and quality of life (secondary endpoints).This trial will include patients with resectable primary tumour in the colon or upper rectum with less than five liver metastases that is possible to treat with surgical resection and/or ablation (RFA/MWA) at time of evaluation.

NCT ID: NCT06199232 Recruiting - Clinical trials for Liver Metastasis Colon Cancer

Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment

Start date: January 23, 2024
Phase: N/A
Study type: Interventional

Hepatic arterial infuison chemothearpy (HAIC), targeted therapy, and programmed death-1 (PD-1) inhibitors have been demonstrated to be effective for colorectal cancer liver metastasis (CRCLM). Thus, the investigators will conduct a prospective trial to explore the efficacy and safety of targeted treatment based on ctDNA genotyping combined with tislelizumab and HAIC as salvage treatment for advanced CRCLM failed from standard systemic treatment, aiming to provide individualized optimized regimen for microsatellite stable (MSS) CRCLM in salvage treatment.

NCT ID: NCT06192030 Recruiting - Clinical trials for Ovarian Metastases of Colorectal Cancer

Machine Learning Predicts Survival and Mutations in Ovarian Metastases of Colorectal Cancer

Start date: August 27, 2022
Phase:
Study type: Observational

The study aimed to develop and validate models to predict survival outcome and key mutations in patients with ovarian metastases of colorectal cancer, as well as to compare the differential gene expression between long-survival group and short-survival group.

NCT ID: NCT06189079 Recruiting - Bone Metastases Clinical Trials

Arterial Embolization for the Treatment of Bone Metastases: Prospective Observational Study

EMBONEMET
Start date: May 10, 2023
Phase:
Study type: Observational [Patient Registry]

To date, arterial embolization constitutes one of the most popular methods in minimally invasive treatment of bone metastases, allowing good results in terms of pain reduction, local control of disease and reduction of peri-operative bleeding, with low invasiveness.

NCT ID: NCT06179602 Recruiting - Clinical trials for Hepatocellular Carcinoma

Prospective Cohort Study on Thermal Ablation of Malignant Liver Tumors

A-IMAGIO
Start date: January 1, 2024
Phase:
Study type: Observational

The endpoint of this study is to develop and validate algorithms, using artificial intelligence and machine learning, to optimize patient selection, treatment planning, treatment evaluation and outcome prediction in patients undergoing thermal ablation of a malignant liver tumor. The long-term objective is to establish thermal ablation as the treatment of choice for the vast majority of patients with a primary or secondary liver tumor by development of an accessible workflow that can be widely implemented in different centers performing thermal ablation. Over a time span of at least four years, data will be collected prospectively, encompassing patient information, tumor characteristics, and treatment details. Additionally, pre-, intra-, and post-procedural imaging will be systematically gathered.

NCT ID: NCT06176352 Recruiting - Clinical trials for Choroidal Neovascularization Secondary to Pathologic Myopia

A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia

POYANG
Start date: March 6, 2024
Phase: Phase 3
Study type: Interventional

This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled study evaluating the efficacy and safety of faricimab in patients with myopic choroidal neovascularization (CNV). This non-inferiority study will compare 6.0 mg faricimab versus 0.5 mg ranibizumab administered at a pro-re-nata (PRN) dosing regimen after an initial active IVT treatment administration at randomization (Day 1).

NCT ID: NCT06175221 Recruiting - Cancer Clinical Trials

Autologous TLPO Vaccine Basket

Start date: November 29, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to learn about TLPO cancer vaccine in cases of solid tumor malignancies. The main objectives it aims to learn about are: - What is the time to progression/recurrence of disease after vaccination with the autologous TLPO vaccine in multiple solid tumor malignancies? - What is the overall survival after vaccination with the autologous TLPO vaccine in multiple solid tumor malignancies? - What are the safety characteristics of autologous TLPO using standardized criteria (Common Terminology Criteria for Adverse Events v5.0) - Does TPLO generate an immune response? - Determine the presence, rate, and duration of any disease control response affected by TPLO.

NCT ID: NCT06174987 Recruiting - Metastatic Cancer Clinical Trials

A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

Start date: January 5, 2024
Phase: Phase 3
Study type: Interventional

This open-label, multicenter, rollover study will provide continued treatment for participants deriving benefit from different therapies received in studies sponsored by Daiichi Sankyo, Inc. (DS) or DS/Astra Zeneca (AZ)-sponsored study (eg. DS8201-A-J101, DS8201-A-U201, DS8201-A-U204, DS8201-A-U207, DS8201-A-U303).

NCT ID: NCT06173401 Recruiting - Spinal Metastases Clinical Trials

Comparing SingLe- Vs Multi-Fraction Spine STereotActic Radiosurgery in Spinal Metastases

Start date: December 18, 2023
Phase: Phase 3
Study type: Interventional

The goal of this study is to determine whether fractionated Stereotactic radiosurgery (SRS) for spine metastases is associated with improved local tumor control compared to single-fraction SRS. Patients will be randomized to treatment with spine SRS using either 22 Gy in 1 fraction or 28 Gy in 2 fractions.